OncoTalks | Oncology Insights at Your Fingertips

Micro-Series | Part 1 | Multiple Myeloma Epidemiology, Pathophysiology and Diagnostics

In part one of four, Dr. Mohit Narang from Maryland Oncology Hematology provides a foundational overview of multiple myeloma.  Tune in to learn how its incidence has evolved over the past thirty years, what we know today about disease risk factors, and the molecular mechanisms underlying multiple myeloma pathophysiology and diagnosis. 
This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Case Journey | ROS1: Transforming NSCLC Patient Outcomes through Precision Testing and Targeted Treatment

In this OncoTalks Case Journey, Dr. Paul Conkling discusses the importance of comprehensive genomic profiling and targeted therapy in non-small cell lung cancer (NSCLC).  Through the lens of two NSCLC patients who received contrasting testing and treatment, listeners learn about the actionable oncogenic biomarker ROS1, which personalized testing methods are most effective for diagnosing ROS1 variants, and the latest advancements in ROS1-targeted therapy. These cases underscore the importance of aligning therapeutic approaches with evidence-based strategies and clinical guidelines by illustrating their direct impact on patient outcomes.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

NSCLC ROS1+ Updates

Live from McKesson Accelerate 2025, Dr. Ira Zackon sits down with Dr. Martin Dietrich to discuss the latest in ROS1+ non-small cell lung cancer. They explore the rarity and significance of ROS1 mutations and clinical presentation. The conversation highlights evolving treatment strategies – from first-generation TKIs to next-generation options – plus safety profiles, resistance mechanisms, and NCCN guideline recommendations. Tune in for practical insights on optimizing therapy and improving outcomes for patients with ROS1+ NSCLC.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

The Power of Precision Medicine for Patients with NSCLC

Live from McKesson Accelerate 2025, host Suzzette Arnal talks with Dr. Melissa Johnson about how precision medicine is reshaping care for non-small cell lung cancer patients. They cover comprehensive biomarker testing, the role of DNA and RNA-based NGS, and why patient characteristics matter. Dr. Johnson also highlights breakthroughs in targeted therapies, emerging immunotherapies, and the critical role of clinical trials in improving outcomes.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

IMforte Trial: Redefining First-Line Maintenance Therapy in ES-SCLC

In this episode of OncoTalks, Dr. Paul Conkling and Dr. Eric Nadler take a deep dive into the IMforte trial—a pivotal phase III global study evaluating lurbinectedin and atezolizumab as a first-line maintenance therapy for extensive-stage small-cell lung cancer (ES-SCLC). They unpack the trial’s design and results, highlighting key safety and efficacy data that led to the FDA’s approval of this combination regimen on October 2, 2025. Tune in to hear expert perspectives on how this new indication will influence clinical practice and improve outcomes for ES-SCLC patients.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

How Comprehensive Molecular Profiling and AI are Shaping the Future of Cancer Care

In this episode, Dr. Paul Conkling and Dr. David Spetzler explore the advantages of broad molecular profiling over smaller panels, emphasizing its superior accuracy in detecting critical biomarkers and identifying eligibility for emerging therapies. They discuss how AI is transforming treatment sequencing and improving patient outcomes, while also highlighting key technical factors—such as microdissection and advanced extraction methods—that enhance the precision of both tissue and liquid biopsies. Dr. Spetzler further addresses the importance of high assay coverage and the role of whole exome and transcriptome sequencing in delivering comprehensive diagnostic insights, along with the challenges of clinical validation and regulatory approval.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

How MRD Testing is Reshaping Breast Cancer Recurrence Monitoring

In this episode of OncoTalks, Dr. Paul Conkling and Dr. Kashif Ali explore how minimal residual disease (MRD) testing using circulating tumor DNA (ctDNA) is reshaping breast cancer management. They discuss how this innovative approach enables the detection of molecular disease that may persist after treatment — often before clinical or radiographic signs appear. Research shows MRD testing can identify recurrence months earlier than conventional methods, allowing for timely intervention and more informed decision-making. As a result, MRD testing is becoming an increasingly valuable tool in personalized cancer care.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Understanding and Addressing Provider Burnout within Community Oncology

In this episode of OncoTalks, Dr. Ira Zackon, Senior Medical Director at Ontada, is joined by Dr. Marcus Neubauer, Medical Director for Professional Wellbeing at The US Oncology Network, to explore the pressing issue of provider burnout in healthcare. Together, they examine the root causes, personal and organizational impacts, and the importance of fostering a culture where provider well-being is not only supported, but expected.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Innovative Genomic Profiling in HR+/HER2- Metastatic Breast Cancer

In this episode of OncoTalks, Dr. Mia Levy and Dr. Paul Conkling discuss new FDA-approved treatments and therapies for HR-positive, HER2-negative metastatic breast cancer. Discover innovative genomic testing techniques that are changing the identification of mutations, paving the way for more precise treatment strategies. Tune in as we spotlight advancements in personalized breast cancer care and learn about the advantages of liquid biopsy testing.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Case Journey | How ADCs are Transforming HER2-Low Metastatic Breast Cancer Treatment

Tune into our debut episode of OncoTalks Case Journey as Dr. Paul Conkling and Dr. Mabel Mardones discuss two compelling cases of metastatic ER-positive breast cancer, emphasizing the role of antibody drug conjugates (ADCs) in treatment. They explore the challenges of HER2-low classification and the importance of early access to innovative therapies for improving patient outcomes. The conversation highlights the need for precise diagnostic approaches and the evolving landscape of breast cancer. 
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.